Literature DB >> 7804987

Public education and cancer of the skin. What do people need to know about melanoma and nonmelanoma skin cancer?

A R Rhodes1.   

Abstract

Cutaneous melanoma (CM) and nonmelanoma skin cancer (NMSC) have a high chance for cure if detected in an early phase of development. Patients who have these tumors may now be treated in the outpatient setting with a minimum of discomfort, inconvenience, and cost. Most skin cancer deaths are caused by CM. Until recently, CM incidence in the United States has been increasing faster than any other potentially lethal cancer, attributable at least in part to aggressive case detection and greater public awareness about the significance of risk factors and early warning signs of evolving tumors, resulting in increased numbers of curable tumors. Most CMs are discovered by patients or close acquaintances. Most CM deaths are related to patient delay in seeking medical care. Patient delay is attributed mostly to lack of knowledge rather than to fear and denial. In the United States, primary prevention of CM and NMSC has focused on encouraging sensible sun-exposure behaviors, while secondary prevention consists of a yearly national campaign that promotes skin awareness and self-examination and free examinations to detect evolving tumors, sponsored by the American Academy of Dermatology and the American Cancer Society. More attention is needed to encourage timely consultation for evolving tumors and predisposing risk factors and to focus screening and surveillance efforts of those people at greatest risk. Public education must continue to promote personal responsibility in the intervention process to reduce the morbidity and mortality associated with CM and NMSC.

Entities:  

Mesh:

Year:  1995        PMID: 7804987     DOI: 10.1002/1097-0142(19950115)75:2+<613::aid-cncr2820751403>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

Review 1.  Basal cell carcinoma.

Authors:  J T Lear; I Harvey; D de Berker; R C Strange; A A Fryer
Journal:  J R Soc Med       Date:  1998-11       Impact factor: 5.344

2.  Skin cancer prevention: a time for action.

Authors:  S A Everett; G A Colditz
Journal:  J Community Health       Date:  1997-06

3.  Population-based study of cutaneous malignant melanoma in the Granada province (Spain), 1985-1992.

Authors:  R Ocaña-Riola; C Martinez-Garcia; S Serrano; A Buendía-Eisman; C Ruiz-Baena; J Canela-Soler
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

4.  Skin cancer prevention education: a national survey of YMCAs.

Authors:  C Rosenberg; J A Mayer; L Eckhardt
Journal:  J Community Health       Date:  1997-10

5.  A national survey of sun safety activities at U.S. zoos.

Authors:  M A Talosig; J A Mayer; L Eckhardt; E C Lewis; H Kwon; G E Belch; L F Eichenfield; J P Elder; M Engelberg
Journal:  J Community Health       Date:  2000-08

Review 6.  Epidemiology and prevention of cutaneous melanoma.

Authors:  Marie-France Demierre
Journal:  Curr Treat Options Oncol       Date:  2006-05

7.  Melanoma survivorship: research opportunities.

Authors:  Susan A Oliveria; Jennifer L Hay; Alan C Geller; Maureen K Heneghan; Mary S McCabe; Allan C Halpern
Journal:  J Cancer Surviv       Date:  2007-03       Impact factor: 4.442

Review 8.  The emerging role of photoacoustic imaging in clinical oncology.

Authors:  Li Lin; Lihong V Wang
Journal:  Nat Rev Clin Oncol       Date:  2022-03-23       Impact factor: 66.675

9.  Recurrence pattern in squamous cell carcinoma of skin of lower extremities and abdominal wall (Kangri cancer) in Kashmir valley of Indian subcontinent: impact of various treatment modalities.

Authors:  Mohmad Ashraf Teli; N A Khan; M Ashraf Darzi; Meenu Gupta; A Tufail
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

10.  Histopathological analysis of the cutaneous changes due to kangri use in kashmiri population: a hospital based study.

Authors:  Iffat Hassan; Peerzada Sajad; Ruby Reshi
Journal:  Indian J Dermatol       Date:  2013-05       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.